NASDAQ NMS - GLOBAL MARKET · PRME
+4.92% · +$0.1450 · Vol 2.0M
Market closed · last close 4:00 PM ET · price as of 19:49:17 ET
Prime Medicine Inc

Prime Medicine Inc

Biotechnology
$3.10
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
PRME
Prime Medicine Inc
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

46/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PRME moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PRME catalysts
About Prime Medicine Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2022
Employees
146
Country
US

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.00
Day high
$3.12
Day low
$2.97
Previous close
$2.95
52W high
$6.67
-53.60% from high
52W low
$2.70
10% of range
Market cap
$558.6M
EPS
$-1.2500
Beta
1.88
Shares out
181.4M
Volume
2M
0.52× rel vol
Avg volume
3.8M
VWAP
$3.05
Price history computed in-house
1W
+5.99%
1M
-26.83%
3M
-3.58%
1Y
-18.23%
YTD
-10.81%
SMA 50 $3.27 · below
SMA 200 $3.64 · below
52W position 10%

PRME overview

Veridion Score
46
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PRME.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PRME Form 4 filings
Public disclosures

Congress activity in PRME

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PRME in the cached public ledger.

Federal contracts

PRME contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PRME in this window.
Lobbying spend

PRME lobbying filings, year to date.

Registered lobbying filings matched to Prime Medicine Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PRME in this window.
Loading news for PRME
Analyst ratings
Sovereign unlock shows live analyst consensus for PRME.
Options
Sovereign unlock shows live options positioning for PRME.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.